The University of Arkansas of Little Rock has received US Patent No. 7,659,062, "Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors." The patent claims oligonucleotide microarrays used to profile and compare gene expression patterns between uterine serous papillary carcinoma and ovarian serous papillary carcinoma or normal endometrial epithelial cells. According to the inventors, mRNA fingerprints identified using the arrays distinguish the more biologically aggressive and chemotherapy resistant USPC from OSPC or NEC. Plasminogen activator inhibitor is the most highly up-regulated gene in OSPC relative to USPC, while the c-erbB2 gene product is overexpressed in USPC relative to OSPC, the inventors write.
High Throughput Genomics of Tucson, Ariz., has received US Patent No. 7,659,063, "High throughput assay system." The patent claims an apparatus and methods for performing multiple, high-throughput, biological or chemical assays, using repeated arrays of probes. The apparatus composes a surface containing an array of generic anchor molecules. The resulting array of probes is used to analyze the presence or test the activity of target molecules that interact with the probes.
Samsung Electronics has received US Patent No. 7,659,388, "Method and compositions for detecting respiratory disease-causing bacterial species." The patent describes a primer set for specifically amplifying target sequences of 12 respiratory disease-causing bacterial species. A probe set specifically hybridizing with target sequences of the 12 species, a microarray composed of the probe set, and a method for detecting a respiratory disease-causing bacterial species using the probe set are also claimed.
Purdue Research Foundation of West Lafayette, Ind., has received US Patent No. 7,659,968, "System with extended range of molecular sensing through integrated multi-modal data acquisition." The patent claims a multi-modal data acquisition system for detecting target material on a biological reaction surface. The system includes a radiation source for generating an incoming beam that impinges on the biological reaction surface at an oblique incidence angle and produces a reflected beam. It also includes an interferometric detector for detecting an interferometric signal from the illuminated surface, a fluorescence detector for detecting a fluorescence signal from the illuminated surface, and a processing system for receiving the interferometric and fluorescence signals and determining the presence or absence of target material on the biological reaction surface.
The Electronics and Telecommunications Research Institute of Daejon, Korea, has received US Patent No. 7,659,983, "Hybrid random bead/chip based microarray." The patent claims an assay that uses microbeads in a solution, where each microbead has a particle substrate with a grating containing a superposition of different predetermined regular periodic variations of the index of refraction along a grating axis and indicative of a code. The microbeads are placed on an alignment substrate, the codes of the microbeads and their position on the alignment substrate are read, the fluorescence on each microbead and the position on the alignment substrate are also read, and an assay result based on bead position order and bead code of the earlier reading steps is determined, according to the patent.
Agilent Technologies has received US Patent No. 7,660,675, "Method and system for analysis of array-based, comparative-hybridization data." The patent claims methods and systems for the analysis of comparative hybridization data, including comparative genomic hybridization data obtained from microarray experiments. The patent claims global noise-based scoring methods for CGH data and methods for identifying sets of contiguous chromosomal DNA subsequences that are amplified or deleted in cells from particular tissue samples. When combined with microarray-based experimental systems, the methods claimed provide increased quantitative precision in the identification of chromosomal abnormalities, including amplified and deleted DNA subsequences based on CGH data, according to the authors.